Legal and clinical experts examined the US medical aid in dying framework, its limits, and ethical debates.
|Articles|June 30, 2013
Supplements and Featured Publications
- Pathways to Success: Utilizing Managed Care Models to Improve Clinical and Economic Outcomes in Diab
- Volume 19
- Issue 8 Suppl
Pathways to Success: Utilizing Managed Care Models to Improve Clinical and Economic Outcomes in Diabetes
Advertisement
Instructions
After reading “Pathways to Success: Utilizing Managed Care Models to Improve Clinical and Economic Outcomes in Diabetes,” complete the program evaluation and select the single best answer to each of the posttest questions.
A statement of continuing education credit will be provided to those physicians and pharmacists who successfully complete and return the answer form and program evaluation and receive a passing grade of 70% or higher on the posttest.
Articles in this issue
over 13 years ago
Current State of Type 2 Diabetes Managementover 13 years ago
Economic Implications of Type 2 Diabetes Managementover 13 years ago
Optimizing Diabetes Management: Managed Care StrategiesAdvertisement
Related to this article
Myeloma faculty from UT Southwestern Medical Center and pharmacy leaders from Texas Oncology discussed how teclistamab- and talquetamab-based regimens are reshaping early relapse in multiple myeloma. Observation-stay economics and physician comfort, not clinical data, are slowing delivery closer to home.
Speakers at IDWeek 2026 urged shifting global health partnerships from donor-recipient models to shared, locally led ownership as funding contracts.
Off-the-shelf CTX110 allogeneic CD19 CAR T shows responses in relapsed/refractory B-cell lymphoma, with manageable cytokine release syndrome.
Declining serum GFAP during MS treatment was tied to lower PIRA risk, supporting its use as a biomarker for treatment response.
David G. Mitchell, PharmD, MBA, CSP, FCPhA, of UC Davis Health, explains how AI-assisted prior authorizations have reduced denials and staff time without replacing pharmacist judgment.
Nearly half of working-age adults were inadequately insured in 2026, and half went without needed care due to cost, a Commonwealth Fund survey found.
Cross-ancestry GWAS of more than 1.8 million people flags SERPINA1, SMAD3, and other bronchiectasis targets shared with COPD and chronic bronchitis.
Advertisement
Advertisement
Trending on AJMC
1
Bepirovirsen Approval Offers New Option for Chronic HBV Treatment
2
Extension Studies in TPIP Show Promise in PAH, PH-ILD
3
Inhaled Amikacin Raises Culture Conversion in New MAC Lung Disease
4
Bronchiectasis GWAS Highlights Candidate Targets Shared With COPD
5